Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk is a well-managed business with long-term growth opportunities. It is the world market leader in diabetes and obesity care.

Novo Nordisk: An Outstanding Company For The Long Term

Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insurance coverage because of a change in job status due to the pandemic. The company also would like...

Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com

In view of the overheated markets, it is worthwhile to take a look at the not so well-trodden paths. However, investors are facing a dilemma. There are a lot of great companies, but only a small number of good investments.

Best Buys For 2021: Don't Choose The Usual U.S. Suspects, Buy Those European Champions Instead

Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.

Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU

Bagsværd, Denmark, 29 December 2020 – Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults.

Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

AbbVie

Abbott Labs

Eli Lilly

Thermo Fisher Scientific

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.

5 Health Care Stocks Outperforming the Benchmark

Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.

Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU

Bagsværd, Denmark 18 December 2020 ­– Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for weight management. The potential indication is for the treatment of adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity.

Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management

Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer's disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities.

Novo Nordisk to enter phase 3 development in Alzheimer's disease with oral semaglutide

ROSELAND, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced the completion of the previously announced transaction whereby Novo Nordisk A/S (“Novo Nordisk”) (NYSE: NVO) acquired Emisphere, on a cash-free, debt-free basis, for $1.35 billion. The consideration paid was $7.83 per share, which was based on the amount of cash and debt of the Company at closing and approximately 170.9 million fully diluted shares outstanding. As a result of the completion of the merger, Emisphere has become a wholly owned subsidiary of Novo Nordisk.

Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 Billion

Biogen

BioNTech SE

CRISPR Therapeutics

Editas Medicine

Roche Holding AG

Sanofi

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

How You Can Profit From the Best-Managed Drugmaker on Earth

Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.

FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda

FDA Approves Label Expansion of Novo Nordisk's (NVO) Saxenda

Bagsværd, Denmark, 7 December 2020 – The Danish Maritime and Commercial High Court has ruled that Novo Nordisk's publication of the press release of 19 September 2019:  "Tresiba® showed an overall lower risk of hypoglycaemia and significantly lower HbA1c when compared to insulin glargine U300 in people with type 2 diabetes" was in violation of the Danish Marketing Practices Act and the Danish Medicines Act. Therefore, Novo Nordisk has been ordered to issue this rectification by which Novo Nordisk withdraws the press release of 19 September 2019.

Novo Nordisk A/S: Rectification

Bagsværd, Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for chronic weight management. A priority review voucher has been applied to the NDA, leading to an anticipated review time of six months from the submission date, according to standard FDA review timelines.

Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management

Aaron's

Aflac

CVS Health

Humana

Intel

These 7 cheap stocks span industry and have a great chance to appreciate in price next year. Click here for the metrics and reasoning.

7 Cheap Stocks to Buy for 2021 That Deserve Recognition

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Emisphere Technologies, Inc. (OTC: EMIS) to Novo Nordisk A/S (NYSE: NVO). Under the terms of the proposed transaction, shareholders of Emisphere will receive only $7.82 in cash for each share of Emisphere that they own. KSF is seeking to determine whether this consideration and the process that led to it are a

EMISPHERE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emisphere Technologies, Inc. - EMIS

Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - Transcript

Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Is Novo Nordisk (NVO) a Suitable Stock for Value Investors?

Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.

Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint

Gilead Sciences

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

Danish pharmaceutical giant Novo Nordisk AS (NYSE:NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.

Novo Acquisition Gives It Unique Drug Delivery Technology

Novo Nordisk, trading near record highs, early Friday announced it would buy a maker of proprietary oral drug delivery technology, a longtime partner, for $1.8 billion, and NVO stock rose. The post Novo Nordisk, Trading Near Highs, Announces $1.8 Billion Acquisition appeared first on Investor's Business Daily.

Novo Nordisk, Trading Near Highs, Announces $1.8 Billion Acquisition

Bagsværd , Denmark, 6 November 202 0 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

News for Novo Nordisk Stock (NVO)